LTI-291
CAS: 1919820-28-2
Ref. 3D-UBD82028
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
LTI-291 is a cholesterol synthesis inhibitor that stabilizes the membrane by inhibiting the cholesterol homeostasis. LTI-291 has been shown to inhibit the biosynthesis of cholesterol, which leads to an increase in the number of cells with low or zero levels of cholesterol. This drug also inhibits HMG-CoA reductase, an enzyme that catalyzes reactions in the mevalonate pathway and is involved in lipid and sterol synthesis. The reduced production of cholesterol leads to a decrease in its concentration within myocardial cells. LTI-291 has been shown to be effective in animal studies as well as clinical trials on humans. It is currently undergoing phase III clinical trials for its use in preventing atherosclerosis.
LTI 291 inhibits cholesterol synthesis by stabilizing cells and inhibiting HMG-CoA reductase, an enzyme involved in lipid and sterol synthesis which leads to a decrease in its concentration within myocardial cells.br>
LTI
Chemical properties
Technical inquiry about: 3D-UBD82028 LTI-291
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
